Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Drug Regulation01:25

Drug Regulation

1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leptin: 30 Years Later.

Annual review of physiology·2025
Same author

Politicizing science funding undermines public trust in science, academic freedom, and the unbiased generation of knowledge.

Frontiers in research metrics and analytics·2024
Same author

Publishing Biomedical Research: <i>a rapidly evolving ecosystem</i>.

Perspectives in biology and medicine·2024
Same author

The Diversity of Institutions Conducting Biomedical Research.

Perspectives in biology and medicine·2024
Same author

Leptin physiology and pathophysiology: knowns and unknowns 30 years after its discovery.

The Journal of clinical investigation·2024
Same author

Moderating "the great debate": The carbohydrate-insulin vs. the energy balance models of obesity.

Cell metabolism·2023

Related Experiment Video

Updated: Jun 13, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.3K

Drug Development Failure: How GLP-1 Development Was Abandoned in 1990.

Jeffrey S Flier

    Perspectives in Biology and Medicine
    |September 9, 2024
    PubMed
    Summary
    This summary is machine-generated.

    The first commercial development of Glucagon-like peptide-1 (GLP-1) drugs for metabolic diseases showed early promise but was abandoned. This historical account offers valuable lessons for modern drug development strategies.

    More Related Videos

    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
    05:58

    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

    Published on: June 25, 2019

    7.4K
    Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
    09:31

    Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

    Published on: November 5, 2016

    7.2K

    Related Experiment Videos

    Last Updated: Jun 13, 2025

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
    11:06

    Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

    Published on: January 31, 2022

    4.3K
    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
    05:58

    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

    Published on: June 25, 2019

    7.4K
    Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
    09:31

    Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

    Published on: November 5, 2016

    7.2K

    Area of Science:

    • Pharmacology
    • Drug Development
    • Medical History

    Background:

    • The Glucagon-like peptide-1 (GLP-1) drug class has become a major success in treating diabetes and obesity.
    • Historical accounts of drug development often focus on successes, neglecting valuable lessons from failures.
    • Understanding past development efforts, including abandoned projects, is crucial for future therapeutic advancements.

    Purpose of the Study:

    • To document the history of the first commercial attempt to develop GLP-1 receptor agonists for metabolic diseases.
    • To analyze the reasons behind the abandonment of this early development program despite initial success.
    • To extract relevant lessons from this historical case study for contemporary drug development.

    Main Methods:

    • Historical case study narrative.
    • Retrospective analysis of a 1990 drug development project.
    • Qualitative insights from a key participant.

    Main Results:

    • The initial commercial effort for GLP-1 drugs for metabolic disease achieved significant early success.
    • Despite promising results, the project was ultimately abandoned in 1990.
    • The reasons for abandonment, though not detailed, offer critical insights into development challenges.

    Conclusions:

    • The early history of GLP-1 drug development provides a valuable, often overlooked, case study.
    • Lessons learned from this abandoned project remain pertinent to current pharmaceutical research and development.
    • Documenting both successes and failures is essential for advancing therapeutic innovation.